Blood pressure control: Where do we stand? Latest data from Italy Tocci G et al. J Hypertens. 2012;30:1065-1074.

Slides:



Advertisements
Similar presentations
Get to Goal, Achieve Control
Advertisements

Is it useful to control blood pressure faster in hypertensive patients? Based on: Gradman AH et al. Hypertension. 2013;61:
1 Mark Huffman, MD, MPH Northwestern University Feinberg School of Medicine Northwestern Memorial Hospital Healthy Transitions 21 November 2013 Blood Pressure.
Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.
Treatment-Resistant Hypertension: Magnitude of the Problem Power Over Pressure
Key messages Stephen S Lim, et al. Lancet 2007; 370:
Resistant hypertension increases patients’ cardiovascular risk 30% of all treated patients develop resistant hypertension [1-5]. Resistant hypertension.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Stroke Issues & prevention. Agenda  Impact of Stroke –Definitions –Epidemiology –Risk factors  Management of Stroke –Acute management –Primary & Secondary.
The concept of Diabetes & CV risk: A lifetime risk challenge
Type 2 diabetes and high blood pressure How explosive is the cocktail?
Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.
To.
Maximum home blood pressure: a novel indicator of target-organ damage in hypertension  Blood pressure variability has recently been shown to be a strong.
Global Immunization Performance Update through 2011.
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
Frank B. Hu et al N Engl J Med 2004; 351: Body-Mass Index and Relative Risk of Death from All Causes during 24 Years of Follow-up.
Blood Pressure Control By Randomized Drug Group In ALLHAT William C. Cushman, Charles E. Ford, Paula T. Einhorn, Jackson T. Wright, Jr., Richard A. Preston,
Ambulatory blood pressure as a predictor of cardiovascular risk: What’s new?
Hypertension the Community - Overview HYPERTENSION IN THE COMMUNITY: OVERVIEW.
Kotseva K, et al. Eur J Cardiovasc Prev Rehabil 2009 Mar 12 [Epub]
Epidemiology of CVD in the Elderly Karen P. Alexander MD Duke University Medical Center Duke Clinical Research Institute Disclosures: (1) Minor Research:
1 Improving Chronic Care Management David M. Cutler Presented at Alliance for Health Reform Novartis/NIHCM Briefing March 28, 2008.
Chronic Care Management Hypertension Results: Represents Health Disparities Collaborative for Hypertension Overall CAP Results.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Utilization Of Lipid-lowering Therapy In Hypertensive Patients In The United States Simon S.K. Tang, MPH* Sean Candrilli, MS** Lizheng Shi, PhD* *Department.
To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE MORTALITY STATISTICS.
To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.
How can you estimate simply the cardiovascular risk of your patients?
לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים.
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients Bramlage P, et al. J Clin Hyper. doi: /j x.
FACTORS THAT INCREASE YOUR RISK OF DEVELOPING HIGH BLOOD PRESSURE: Family history of high blood pressure Race (African-Americans are more likely to.
Renal damage occurs in 1 out of 4 hypertensives Adapted from Leoncini et al. J Hypertens. 2008;26:
Slide 1 Downloaded from Population Impact of Losartan Use on Stroke in the European Union (EU)
7 April 2013 WORLD HEALTH DAY. World Health Day 2 On 7 April 1948, the World Health Organization (WHO) was created. Since then, WHO named April 7 as World.
Ethnicity and Cardiovascular Disease Africans Americans.
Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.
2007 Hypertension as a Public Health Risk January, 2007.
Food and cardiovascular heart disease Pedro Marques-Vidal IUMSP Lausanne, Switzerland.
Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements Reference:
The widespread decline in cardiovascular mortality : A poorly understood triumph David Leon London School of Hygiene & Tropical Medicine Arctic University.
Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial
Assef Hamdan, MD Intern Doctor at Palestinian MoH
Hypertension guidelines What’s all the controversy about 2015
Blood Pressure and Age in Controlling Hypertension
CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.
United States Preventive Services Task Force: Recommendations for ABPM
Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.
Improving Chronic Care Management
Teaching Tool: Blood Pressure Classification
برنامه راهبردی پیشگیری و کنترل بیماری های قلبی عروقی
Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment 
A. Heart failure: A challenge to the healthcare delivery system
The Hypertension in the Very Elderly Trial (HYVET)
MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those
VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Alan Gradman  Journal of Indian College of Cardiology 
Global burden of hypertension in the adult population
End point Net change with soy supplements vs control (95% CI) p
Lowering of SBP by 20 mm Hg Reduces Cardiovascular Risk by Half
Level of risk factor control in the overall sample and by gender
Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%
Measurement of Blood Pressure: Issues and Challenges
DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,
Flow chart of the 1683 study members at age 60–64 years by hypertension (HT) status. Flow chart of the 1683 study members at age 60–64 years by hypertension.
JNC Evidence-Based Guideline for the Management of
Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.
Presentation transcript:

Blood pressure control: Where do we stand? Latest data from Italy Tocci G et al. J Hypertens. 2012;30:

Hypertension still the biggest issue 1.56 billion hypertensive patients in the world in million new cases of hypertension per year 1 High blood pressure is the first cause of death and burden around the world 2 1.Kearney et al. Lancet. 2005; 365: Ezzati et al. N Engl J Med. 2013;369:

A developed country case: Italy Analysis of the largest, representative and updated sample of hypertensive patients in Italy From the most recent observational studies available over the last 5 years ( ) – hypertensive patients – Mean age 56.6 years, 60% women, BMI 27.2 – Mostly in general practice Tocci G et al. J Hypertens. 2012;30:

Only 57% of the hypertensive population is treated Tocci G et al. J Hypertens. 2012;30:

37% of the treated hypertensive population have controlled blood pressure Tocci G et al. J Hypertens. 2012;30:

Evolution of hypertension management between 1999 and 2011 In 1999In % treated and controlled patients 37% treated and controlled patients GPs154.1/90.9 mm Hg143.5/84.8 mm Hg Specialists147.2/89.6 mm Hg146.5/88.5 mm Hg SBP/DBP Tocci G. et al. J Hypertens. 2012;30:

More than 70% of the hypertensive population have grade 1 hypertension Tocci G et al. J Hypertens. 2012;30: Blood pressure stratification among the studied population (treated or untreated)

The French example: the majority of untreated patients have grade 1 hypertension Lang T et al. Hypertension. 2001;38: Blood pressure stratification in untreated hypertensive people in a working population, in France.

Conclusion Despite hypertension management improvement since 1999, 1 hypertension is the 1 st risk factor for cardiovascular disease. 2 1 out 3 deaths is due to cardiovascular disease (2007). 3 The Italian case shows an inadequate control of blood pressure in a developed country. 1 Only 37% of treated patients are controlled. 1 International guidelines advise controlling blood pressure below 140/90 mm Hg. 4 Most uncontrolled treated patients have grade 1 hypertension. 5 Each increase of 20/10 mm Hg (SBP/DBP) doubles the risk of cardiovascular death Tocci G et al. J Hypertens. 2012;30: Hobbs, Richard FD. Vasc Health Risk Manag. 2007;3: Roger VL et al. Circulation. 2011;123:e18-e Mancia G et al. Eur Heart J. 2013;34: Lang T et al. Hypertension. 2001;38: Lewington S et al; Prospective Studies Collaboration. Lancet. 2002;360: